Research programme: vaccines - Akshaya Bio

Drug Profile

Research programme: vaccines - Akshaya Bio

Latest Information Update: 12 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Akshaya Bio
  • Developer Akshaya Bio; Nuron Biotech
  • Class Antimalarials; Cancer vaccines; Hepatitis B vaccines; Hepatitis C vaccines; Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B; Hepatitis C; HIV infections

Highest Development Phases

  • Preclinical Alphavirus infections; Hepatitis B; Hepatitis C; HIV infections; Influenza virus infections; Malaria
  • Research Cancer

Most Recent Events

  • 11 Aug 2016 Hepatitis B, Hepatitis C and HIV vaccines are available for licensing as of 31 Dec 2015.
  • 31 Dec 2015 Early research in Cancer in Canada (Parenteral) (3195687; before December 2015)
  • 31 Dec 2015 Akshaya Bio plans a phase Ia and a phase Ib trial for Hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top